MedPath

Digoxin

Generic Name
Digoxin
Brand Names
Digox, Lanoxin
Drug Type
Small Molecule
Chemical Formula
C41H64O14
CAS Number
20830-75-5
Unique Ingredient Identifier
73K4184T59
Background

Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s.

Indication

Digoxin is indicated in the following conditions: 1) For the treatment of mild to moderate heart failure in adult patients. 2) To increase myocardial contraction in children diagnosed with heart failure. 3) To maintain control ventricular rate in adult patients diagnosed with chronic atrial fibrillation.

In adults with heart failure, when it is clinically possible, digoxin should be administered in conjunction with a diuretic and an angiotensin-converting enzyme (ACE) inhibitor for optimum effects.

Associated Conditions
Myocardial contractility, Ventricular Arrhythmia, Mild to moderate heart failure

A Drug-Drug Interaction Study of Orforglipron (LY3502970) in Healthy Overweight and Obese Participants

First Posted Date
2024-01-02
Last Posted Date
2024-07-22
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
50
Registration Number
NCT06186622
Locations
🇺🇸

Fortrea Clinical Research Unit Inc., Dallas, Texas, United States

Clinical Trial to Assess Effect of Verapamil on Systemic Exposure of EP395 and Effect of EP395 on Systemic Exposure of Midazolam and Digoxin

Phase 1
Completed
Conditions
Chronic Obstructive Pulmonary Disease Exacerbation
COPD
Interventions
First Posted Date
2023-11-07
Last Posted Date
2024-02-28
Lead Sponsor
EpiEndo Pharmaceuticals
Target Recruit Count
37
Registration Number
NCT06118684
Locations
🇸🇪

Clinical Trial Consultants AB, Uppsala, Sweden

A Drug-Drug Interaction Study of LY3537982 on Midazolam, Digoxin, and Rosuvastatin in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2023-11-01
Last Posted Date
2024-11-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
35
Registration Number
NCT06111521
Locations
🇺🇸

ICON Early Clinical & Bioanalytical Solutions, Salt Lake City, Utah, United States

A Drug-Drug Interaction Study Evaluating the Perpetrator Potential of DC-806 on Cocktails of CYP450 Enzyme and Transporter Substrates in Healthy Participants

Phase 1
Completed
Conditions
Healthy Participants
Interventions
First Posted Date
2023-10-23
Last Posted Date
2024-01-11
Lead Sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Target Recruit Count
28
Registration Number
NCT06092931
Locations
🇺🇸

ICON Phase 1 Clinic, Salt Lake City, Utah, United States

Drug-durg Interaction of ZSP1273 With Digoxin, Rosuvastatin,Itraconazole and Probenecid

Phase 1
Completed
Conditions
Drug Drug Interaction
Interventions
First Posted Date
2023-07-20
Last Posted Date
2024-01-29
Lead Sponsor
Guangdong Raynovent Biotech Co., Ltd
Target Recruit Count
49
Registration Number
NCT05954624
Locations
🇨🇳

The First Affiliated Hospital of Guangzhou University of Chinese medicine, Guangzhou, China

A Study to Evaluate the Drug-drug Interaction Potential of BMS-986196 in Healthy Participants

First Posted Date
2023-05-10
Last Posted Date
2023-09-26
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
18
Registration Number
NCT05852769
Locations
🇺🇸

ICON plc, Millcreek, Utah, United States

A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid Tumors

Phase 1
Withdrawn
Conditions
Advanced Solid Tumor
Metastatic Solid Tumor
Interventions
First Posted Date
2023-04-25
Last Posted Date
2025-04-01
Lead Sponsor
Turning Point Therapeutics, Inc.
Target Recruit Count
12
Registration Number
NCT05828303
Locations
🇺🇸

Local Institution - 2101, Canton, Ohio, United States

🇺🇸

Gabrail Cancer Research Center, Canton, Ohio, United States

🇦🇺

Local Institution - 2119, Westmead, New South Wales, Australia

and more 30 locations

A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects

Phase 1
Completed
Conditions
Overweight Subjects
Obese Subjects
Interventions
First Posted Date
2023-04-18
Last Posted Date
2023-11-14
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Target Recruit Count
48
Registration Number
NCT05815680
Locations
🇨🇳

Aerospace Center Hospital, Beijing, Beijing, China

A Study to Evaluate the Drug-drug Interactions (DDIs) of GP681 With Rosuvastatin, Digoxin, Itraconazole, Oseltamivir in Chinese Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteers
Interventions
First Posted Date
2023-03-29
Last Posted Date
2023-11-14
Lead Sponsor
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Target Recruit Count
54
Registration Number
NCT05789342
Locations
🇨🇳

China-Japan Friendship Hospital, Beijing, China

A Study to Assess the Effects of Savolitinib on the Pharmacokinetics of Digoxin, Rosuvastatin, Metformin, and Furosemide in Healthy Male Subjects

First Posted Date
2023-03-14
Last Posted Date
2023-07-13
Lead Sponsor
AstraZeneca
Target Recruit Count
6
Registration Number
NCT05768360
Locations
🇩🇪

Research Site, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath